First Hospital to Deploy 2nd Senhance Surgical System
RESEARCH TRIANGLE PARK, NC, January 3, 2023 (GLOBE NEWSWIRE) — Assensus Surgical (NYSE American: ASXC), a medical device company pioneering a new era of Performance-Guided Surgery™ by digitizing the interface between surgeons and patients, today announced Kitakyushu General Hospital Kitakyushu Hospital, a hospital in the Kyushu region of Japan, has signed an agreement to lease and utilize a second Senhance® Surgical System at the end of December 2022.
Since launching its first Senhance system in January 2020, the hospital has completed more than 300 surgeries using performance-guided surgery.
Anthony Fernando, President and CEO of Asensus Surgical, said: “This milestone speaks to the clinical value that the Senhance System and Intelligent Surgical Unit™ bring to surgeons and hospitals, and the broad applicability of the system for many different types of procedures across multiple specialties.”
Asensus Surgical’s technology platform, the Senhance Surgical System, is the first digital laparoscopic platform of its kind to leverage augmented intelligence to deliver unparalleled performance and patient outcomes through machine learning. Senhance goes beyond typical surgical robotic systems to provide surgical assurance through haptic feedback, eye-tracking camera control, and 3D visualization, enabling 3 mm instruments (the world’s smallest instruments available on a robotic surgical platform) First platform to offer. The Senhance Surgical System is equipped with the Intelligent Surgical Unit™ (ISU™). By responding to commands and recognizing specific objects and positions within the surgical field, the ISU enables control of a machine vision-driven surgeon’s camera, allowing the surgeon to visualize a field of view using instrument movement. allow you to change the
Dr. Naoki Nagata, Director of Kitakyushu General Hospital, said: “Over the past three years, we have received very positive feedback from Senhance surgeons and patients, and we are pleased to expand the use of the Senhance system to provide better and safer outcomes for our patients.”
About Kitakyushu General Hospital
Kitakyushu General Hospital is a prestigious hospital and is recognized as one of the major hospitals in Kitakyushu. We are the core of the Kitakyushu Hospital Group, which combines advanced medical care and emergency medical care. The only general hospital in the Kitakyushu Hospital Group with a 360-bed emergency medical center.
About Assensus Surgical
Asensus Surgical, Inc. Ushers in a New Era of Performance-Guided Surgery by Digitizing the Surgeon-Patient Interface to Unlock the Surgeon’s Clinical Intelligence, Enabling Consistently Superior Outcomes and a New Standard in Surgery is developing. It builds on the foundation of digital laparoscopy with the Senhance Surgical System, powered by an Intelligent Surgical Unit (ISU), giving the surgeon greater control and reduced surgical variability. By adding machine vision, augmented intelligence, and deep learning capabilities to the entire surgical experience, we plan to holistically address the current clinical, cognitive, and economic shortcomings that drive outcome- and value-based care in surgery. . Learn more about performance-guided surgery and digital laparoscopy with the Senhance Surgical System here. www.senhance.comCurrently available in the US, EU, Japan, Russia, and some other countries. See below for a complete list of indications for use. www.senhance.com/indications. For more information, see: www.asensus.com.
assensus
Email alert: https://ir.asensus.com/email-alerts
LinkedIn: https://www.linkedin.com/company/asensus-surgical-inc
twitter: https://twitter.com/AsensusSurgical
Youtube: https://www.youtube.com/c/transenterix
video: https://vimeo.com/asxc
Tick tock: https://www.tiktok.com/@asensus_surgical
Forward-Looking Statements
This press release includes statements regarding the Senhance Surgical System and Kitakyushu General Hospital’s launch of a second Senhance Surgical System. These statements and other statements regarding the Company’s future plans and objectives constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934; Responsibilities established by the Private Securities Litigation Reform Act. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and could cause results to differ materially from expectations. Kitakyushu General Hospital discusses the clinical value the Senhance system and ISU bring to surgeons and hospitals, and whether Kitakyushu General Hospital’s expanded use of the Senhance system will lead to better and safer outcomes for patients. For a discussion of the risks and uncertainties associated with our business, please see the Securities and Exchange Commission (SEC ), please check the documents submitted to February 28, 2022 and other filings we filed with the SEC. These forward-looking statements are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contact:
Mark Klausner or Mike Vallee, 443-213-0499
Investment@asensus.com
Media Contact:
Isabella Rodriguez, 708-833-1572
CG life
irodriguez@cglife.com
